Prevention of rotavirus disease: Guidelines for use of rotavirus vaccine

N. A. Halsey, J. S. Abramson, P. J. Chesney, M. C. Fisher, M. A. Gerber, S. M. Marcy, D. L. Murray, G. D. Overturf, C. G. Prober, T. N. Saari, L. B. Weiner, R. J. Whitley, C. Baker, G. Peter, L. K. Pickering, A. Hirsch, R. F. Jacobs, N. E. MacDonald, B. Schwartz, W. A. OrensteinM. C. Hardegree, N. R. Rabinovich, R. F. Breiman

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Virtually all children experience rotavirus (Rv) infection before school entry. In the United States and other temperate countries, Rv disease peaks in the winter and during this time is responsible for the majority of episodes of diarrhea in infants and young children. Data collected by the Centers for Disease Control and Prevention from 1979 through 1992 indicate that approximately 50 000 hospitalizations attributable to Rv occur annually in the United States, a number that approximates about 1 in 78 children being hospitalized with Rv diarrhea by 5 years of age. RotaShield (Wyeth-Lederle Vaccines and Pediatrics, Philadelphia, PA) was licensed by the Food and Drug Administration on August 31, 1998, for oral administration to infants at 2, 4, and 6 months of age. The rationale for using Rv immunization for prevention or modification of Rv disease is based on several considerations. First, the rate of illness attributable to Rv among children is comparable in industrialized and developing countries, which indicates that improved public sanitation is unlikely to decrease the incidence of disease. Second, although implementation of oral rehydration programs to prevent dehydration has improved in the United States, widespread use is inadequate to prevent significant morbidity. Third, trials of rhesus rotavirus-tetravalent (Rv) vaccine in the United States, Finland, and Venezuela show efficacy rates of approximately 80% for prevention of severe illness and 48% to 68% against Rv- induced diarrheal episodes. These results are similar to the protection observed after natural Rv infection, which also confers better protection against subsequent episodes of severe disease than against mild illness. This statement provides recommendations regarding the use of Rv vaccine in infants in the United States.

Original languageEnglish (US)
Pages (from-to)1483-1491
Number of pages9
JournalPediatrics
Volume102
Issue number6
DOIs
StatePublished - Jan 1 1998

Fingerprint

Rotavirus Vaccines
Rotavirus
Guidelines
Rotavirus Infections
Diarrhea
Venezuela
Hospitalized Child
Sanitation
Fluid Therapy
United States Food and Drug Administration
Finland
Centers for Disease Control and Prevention (U.S.)
Dehydration
Developed Countries
Developing Countries
Oral Administration
Immunization
Hospitalization
Vaccines
Pediatrics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Halsey, N. A., Abramson, J. S., Chesney, P. J., Fisher, M. C., Gerber, M. A., Marcy, S. M., ... Breiman, R. F. (1998). Prevention of rotavirus disease: Guidelines for use of rotavirus vaccine. Pediatrics, 102(6), 1483-1491. https://doi.org/10.1542/peds.102.6.1483

Prevention of rotavirus disease : Guidelines for use of rotavirus vaccine. / Halsey, N. A.; Abramson, J. S.; Chesney, P. J.; Fisher, M. C.; Gerber, M. A.; Marcy, S. M.; Murray, D. L.; Overturf, G. D.; Prober, C. G.; Saari, T. N.; Weiner, L. B.; Whitley, R. J.; Baker, C.; Peter, G.; Pickering, L. K.; Hirsch, A.; Jacobs, R. F.; MacDonald, N. E.; Schwartz, B.; Orenstein, W. A.; Hardegree, M. C.; Rabinovich, N. R.; Breiman, R. F.

In: Pediatrics, Vol. 102, No. 6, 01.01.1998, p. 1483-1491.

Research output: Contribution to journalArticle

Halsey, NA, Abramson, JS, Chesney, PJ, Fisher, MC, Gerber, MA, Marcy, SM, Murray, DL, Overturf, GD, Prober, CG, Saari, TN, Weiner, LB, Whitley, RJ, Baker, C, Peter, G, Pickering, LK, Hirsch, A, Jacobs, RF, MacDonald, NE, Schwartz, B, Orenstein, WA, Hardegree, MC, Rabinovich, NR & Breiman, RF 1998, 'Prevention of rotavirus disease: Guidelines for use of rotavirus vaccine', Pediatrics, vol. 102, no. 6, pp. 1483-1491. https://doi.org/10.1542/peds.102.6.1483
Halsey NA, Abramson JS, Chesney PJ, Fisher MC, Gerber MA, Marcy SM et al. Prevention of rotavirus disease: Guidelines for use of rotavirus vaccine. Pediatrics. 1998 Jan 1;102(6):1483-1491. https://doi.org/10.1542/peds.102.6.1483
Halsey, N. A. ; Abramson, J. S. ; Chesney, P. J. ; Fisher, M. C. ; Gerber, M. A. ; Marcy, S. M. ; Murray, D. L. ; Overturf, G. D. ; Prober, C. G. ; Saari, T. N. ; Weiner, L. B. ; Whitley, R. J. ; Baker, C. ; Peter, G. ; Pickering, L. K. ; Hirsch, A. ; Jacobs, R. F. ; MacDonald, N. E. ; Schwartz, B. ; Orenstein, W. A. ; Hardegree, M. C. ; Rabinovich, N. R. ; Breiman, R. F. / Prevention of rotavirus disease : Guidelines for use of rotavirus vaccine. In: Pediatrics. 1998 ; Vol. 102, No. 6. pp. 1483-1491.
@article{4c9834739bd745ee91644bd73f21ddc3,
title = "Prevention of rotavirus disease: Guidelines for use of rotavirus vaccine",
abstract = "Virtually all children experience rotavirus (Rv) infection before school entry. In the United States and other temperate countries, Rv disease peaks in the winter and during this time is responsible for the majority of episodes of diarrhea in infants and young children. Data collected by the Centers for Disease Control and Prevention from 1979 through 1992 indicate that approximately 50 000 hospitalizations attributable to Rv occur annually in the United States, a number that approximates about 1 in 78 children being hospitalized with Rv diarrhea by 5 years of age. RotaShield (Wyeth-Lederle Vaccines and Pediatrics, Philadelphia, PA) was licensed by the Food and Drug Administration on August 31, 1998, for oral administration to infants at 2, 4, and 6 months of age. The rationale for using Rv immunization for prevention or modification of Rv disease is based on several considerations. First, the rate of illness attributable to Rv among children is comparable in industrialized and developing countries, which indicates that improved public sanitation is unlikely to decrease the incidence of disease. Second, although implementation of oral rehydration programs to prevent dehydration has improved in the United States, widespread use is inadequate to prevent significant morbidity. Third, trials of rhesus rotavirus-tetravalent (Rv) vaccine in the United States, Finland, and Venezuela show efficacy rates of approximately 80{\%} for prevention of severe illness and 48{\%} to 68{\%} against Rv- induced diarrheal episodes. These results are similar to the protection observed after natural Rv infection, which also confers better protection against subsequent episodes of severe disease than against mild illness. This statement provides recommendations regarding the use of Rv vaccine in infants in the United States.",
author = "Halsey, {N. A.} and Abramson, {J. S.} and Chesney, {P. J.} and Fisher, {M. C.} and Gerber, {M. A.} and Marcy, {S. M.} and Murray, {D. L.} and Overturf, {G. D.} and Prober, {C. G.} and Saari, {T. N.} and Weiner, {L. B.} and Whitley, {R. J.} and C. Baker and G. Peter and Pickering, {L. K.} and A. Hirsch and Jacobs, {R. F.} and MacDonald, {N. E.} and B. Schwartz and Orenstein, {W. A.} and Hardegree, {M. C.} and Rabinovich, {N. R.} and Breiman, {R. F.}",
year = "1998",
month = "1",
day = "1",
doi = "10.1542/peds.102.6.1483",
language = "English (US)",
volume = "102",
pages = "1483--1491",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "6",

}

TY - JOUR

T1 - Prevention of rotavirus disease

T2 - Guidelines for use of rotavirus vaccine

AU - Halsey, N. A.

AU - Abramson, J. S.

AU - Chesney, P. J.

AU - Fisher, M. C.

AU - Gerber, M. A.

AU - Marcy, S. M.

AU - Murray, D. L.

AU - Overturf, G. D.

AU - Prober, C. G.

AU - Saari, T. N.

AU - Weiner, L. B.

AU - Whitley, R. J.

AU - Baker, C.

AU - Peter, G.

AU - Pickering, L. K.

AU - Hirsch, A.

AU - Jacobs, R. F.

AU - MacDonald, N. E.

AU - Schwartz, B.

AU - Orenstein, W. A.

AU - Hardegree, M. C.

AU - Rabinovich, N. R.

AU - Breiman, R. F.

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Virtually all children experience rotavirus (Rv) infection before school entry. In the United States and other temperate countries, Rv disease peaks in the winter and during this time is responsible for the majority of episodes of diarrhea in infants and young children. Data collected by the Centers for Disease Control and Prevention from 1979 through 1992 indicate that approximately 50 000 hospitalizations attributable to Rv occur annually in the United States, a number that approximates about 1 in 78 children being hospitalized with Rv diarrhea by 5 years of age. RotaShield (Wyeth-Lederle Vaccines and Pediatrics, Philadelphia, PA) was licensed by the Food and Drug Administration on August 31, 1998, for oral administration to infants at 2, 4, and 6 months of age. The rationale for using Rv immunization for prevention or modification of Rv disease is based on several considerations. First, the rate of illness attributable to Rv among children is comparable in industrialized and developing countries, which indicates that improved public sanitation is unlikely to decrease the incidence of disease. Second, although implementation of oral rehydration programs to prevent dehydration has improved in the United States, widespread use is inadequate to prevent significant morbidity. Third, trials of rhesus rotavirus-tetravalent (Rv) vaccine in the United States, Finland, and Venezuela show efficacy rates of approximately 80% for prevention of severe illness and 48% to 68% against Rv- induced diarrheal episodes. These results are similar to the protection observed after natural Rv infection, which also confers better protection against subsequent episodes of severe disease than against mild illness. This statement provides recommendations regarding the use of Rv vaccine in infants in the United States.

AB - Virtually all children experience rotavirus (Rv) infection before school entry. In the United States and other temperate countries, Rv disease peaks in the winter and during this time is responsible for the majority of episodes of diarrhea in infants and young children. Data collected by the Centers for Disease Control and Prevention from 1979 through 1992 indicate that approximately 50 000 hospitalizations attributable to Rv occur annually in the United States, a number that approximates about 1 in 78 children being hospitalized with Rv diarrhea by 5 years of age. RotaShield (Wyeth-Lederle Vaccines and Pediatrics, Philadelphia, PA) was licensed by the Food and Drug Administration on August 31, 1998, for oral administration to infants at 2, 4, and 6 months of age. The rationale for using Rv immunization for prevention or modification of Rv disease is based on several considerations. First, the rate of illness attributable to Rv among children is comparable in industrialized and developing countries, which indicates that improved public sanitation is unlikely to decrease the incidence of disease. Second, although implementation of oral rehydration programs to prevent dehydration has improved in the United States, widespread use is inadequate to prevent significant morbidity. Third, trials of rhesus rotavirus-tetravalent (Rv) vaccine in the United States, Finland, and Venezuela show efficacy rates of approximately 80% for prevention of severe illness and 48% to 68% against Rv- induced diarrheal episodes. These results are similar to the protection observed after natural Rv infection, which also confers better protection against subsequent episodes of severe disease than against mild illness. This statement provides recommendations regarding the use of Rv vaccine in infants in the United States.

UR - http://www.scopus.com/inward/record.url?scp=0031741756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031741756&partnerID=8YFLogxK

U2 - 10.1542/peds.102.6.1483

DO - 10.1542/peds.102.6.1483

M3 - Article

C2 - 9832589

AN - SCOPUS:0031741756

VL - 102

SP - 1483

EP - 1491

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 6

ER -